Summary
Gilead Sciences, Inc. (GILD) filed an 8-K report on February 4, 2008, detailing compensation arrangements for its named executive officers as of January 30, 2008. The report outlines the 2007 bonus awards and 2008 base salaries, reflecting the company's performance and individual contributions. Notably, the report also discloses the grant of stock options and performance shares for the 2008 fiscal year, designed to incentivize long-term growth and alignment with shareholder interests. The performance share awards are particularly significant, as their conversion into actual shares is directly tied to Gilead's total shareholder return (TSR) and revenue growth relative to a peer group of biotech and pharmaceutical companies over a three-year period. This structure aims to ensure that executive compensation is heavily influenced by the company's ability to outperform its industry peers, a move that should be of interest to investors focused on executive accountability and long-term value creation.
Key Highlights
- 1The Compensation Committee set 2008 base salaries and determined 2007 bonus awards for named executive officers.
- 2John C. Martin, CEO, received a 2007 bonus of $1,617,000 and a 2008 base salary of $1,155,000.
- 3Executive compensation is linked to both individual performance and company-wide financial and non-financial objectives.
- 4Stock options were granted with an exercise price of $43.15, vesting over five years.
- 5Performance shares were granted, with their conversion dependent on Gilead's Total Shareholder Return (TSR) and revenue growth relative to the AMEX Biotech-Pharmaceutical Index over a three-year period (2008-2010).
- 6Performance shares can convert into 0% to 200% of the granted number of shares based on relative performance.
- 7Specific provisions exist for accelerated vesting of performance shares in cases of death, disability, or change in control.